The Obama administration finalized a rule that would fine drug makers for overcharging hospitals, clinics, and other providers for medicines that are purchased under the federal government’s 340B drug discount program.

Under the rule, which was issued on Wednesday by the US Human Resources and Service Administration, drug makers could be fined up to $5,000 for each instance in which they “knowingly and intentionally” overcharge for their medicines. The companies must also reimburse providers for medicines that were purchased.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for our biotech newsletter, The Readout

Get our guide to what's new in biotech delivered each morning.

Recommended Stories